

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

June 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

| | |
|---|---|
| Summary of decisions effective 1 June 2024..... | 3 |
| Section H changes to Part II | 5 |
| Index..... | 7 |

Summary of decisions

EFFECTIVE 1 JUNE 2024

- Atazanavir sulphate (Atazanavir Mylan) cap 200 mg – removal of PSS and to be delisted from 1 December 2024
- Atazanavir sulphate (Atazanavir Viartis) cap 200 mg – addition of PSS
- Ciprofloxacin (Ipsa-Ciprofloxacin) tab 250 mg and 500 mg – new listing and addition of PSS
- Ciprofloxacin tab 250 mg (Cipflox) and tab 500 mg (Ciprofloxacin – Torrent) – to be delisted from 1 November 2024.
- Choline salicylate with cetalkonium chloride adhesive gel 8.7% with cetalkonium chloride 0.01% – delisted from 1 June 2024
- Cytarabine (Cytarabine DBL) inj 100 mg per ml, 20 ml vial – new listing
- Fluocortolone caproate with fluocortolone pivalate and cinchocaine (Ultraproct) oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g – price increase
- Fluocortolone caproate with fluocortolone pivalate and cinchocaine (Ultraproct) suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg – price increase
- Levosimendan (Simdax) inj 2.5 mg per ml, 5 ml vial – new listing and addition of PSS
- Midazolam (Midazolam Viartis) inj 1 mg per ml, 5 ml ampoule – new listing
- Morphine sulphate (Oramorph CDC S29) oral liq 2 mg per ml, 100 ml – new listing
- Multivitamins (e.g. Pabrinex IM) inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1) – example brand to be delisted from 1 June 2024
- Multivitamins (e.g. Pabrinex IV) inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1) – example brand to be delisted from 1 June 2024
- Nadolol (Nadolol BNM) tab 40 mg and 80 mg – extended HSS expiry date
- Octreotide (Sandostatin LAR) inj depot 30 mg prefilled syringe – new listing
- Octreotide (Octreotide Depot Teva) inj depot 30 mg prefilled syringe – to be delisted from 1 December 2024
- Oxycodone hydrochloride (Oxycodone Lucis S29) oral liq 5 mg per 5 ml, 250 ml – new listing
- Simvastatin (Simvastatin Mylan) tab 80 mg – removal of PSS
- Simvastatin (Simvastatin Viartis) tab 40 mg and 80 mg – addition of PSS

Summary of decisions – effective 1 June 2024 (continued)

- Simvastatin (Simvastatin Mylan) tab 40 mg – removal of PSS and to be delisted from 1 December 2024
- Sodium chloride (InterPharma) irrigation soln 0.9%, 30 ml ampoule – price increase
- Sulfadiazine sodium tab 500 mg – amended chemical name

| Price (ex man. Excl. GST) \$ | Per | Brand or Generic Manufacturer |
|------------------------------------|-----|-------------------------------------|
|------------------------------------|-----|-------------------------------------|

Section H changes to Part II

Effective 1 June 2024

ALIMENTARY TRACT AND METABOLISM

| | | | |
|----|---|------|--|
| 7 | FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE (↑ price) Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g 13.05 | 30 g | Ultraproct |
| | Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg 8.61 | 12 | Ultraproct |
| 23 | CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE (delisting) Adhesive gel 8.7% with cetalkonium chloride 0.01% Note – Choline salicylate with cetalkonium chloride delisted from 1 June 2024 | | |
| 25 | MULTIVITAMINS (delisting example brand only) Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1) Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1) | | <i>e.g. Pabrinex IM</i> <i>e.g. Pabrinex IV</i> |
| | Note – e.g. Pabrinex IM and e.g. Pabrinex IV to be delisted from 1 June 2024 | | |

CARDIOVASCULAR SYSTEM

| | | | |
|----|--|-----|---------------------|
| 46 | NADOLOL (extended HSS expiry date) Tab 40 mg – 1% DV Mar-22 to 2024 2027 19.19 | 100 | Nadolol BNM |
| | Tab 80 mg – 1% DV Mar-22 to 2024 2027 30.39 | 100 | Nadolol BNM |
| 51 | LEVOSIMENDAN (new listing and addition of PSS) → Inj 2.5 mg per ml, 5 ml vial – 5% DV Nov-24 to 2027 509.60 | 1 | Simdax |
| 52 | SIMVASTATIN (removal of PSS and delisting) Tab 40 mg – 5% DV Mar-24 to 2026 31/05/2024 4.11 | 90 | Simvastatin Mylan |
| | Tab 80 mg – 5% DV Mar-24 to 2026 31/05/2024 8.81 | 90 | Simvastatin Mylan |
| | Note – Simvastatin Mylan tab 40 mg to be delisted from 1 December 2024 | | |
| 52 | SIMVASTATIN (addition of PSS) Tab 40 mg – 5% DV Jun-24 to 2026 4.11 | 90 | Simvastatin Viatris |
| | Tab 80 mg – 5% DV Jun-24 to 2026 8.81 | 90 | Simvastatin Viatris |

INFECTIONS

| | | | |
|----|---|----|--------------------|
| 91 | CIPROFLOXACIN (new listing and addition of PSS) → Tab 250 mg – 5% DV Nov-24 to 2026 1.95 | 28 | Ipca-Ciprofloxacin |
| | → Tab 500 mg – 5% DV Nov-24 to 2026 3.10 | 28 | Ipca-Ciprofloxacin |
| | Note – Cipflox tab 250 mg and Ciprofloxacin – Torrent tab 500 mg to be delisted from 1 November 2024. | | |
| 99 | SULFPHADIAZINE SODIUM (amended chemical name) → Tab 500 mg | | |

| | Price (ex man. Excl. GST) \$ | Per | Brand or Generic Manufacturer |
|--|------------------------------------|-----|-------------------------------------|
|--|------------------------------------|-----|-------------------------------------|

Changes to Section H Part II – effective 1 June 2024 (continued)

| | | | | |
|-----|---|--------|----|---------------------------|
| 103 | ATAZANAVIR SULPHATE (removal of PSS and delisting) → Cap 200 mg – 5% DV May-23 to 2025 31/05/2024 | 110.00 | 60 | Atazanavir Mylan |
| | Note – Atazanavir Mylan cap 200 mg to be delisted from 1 December 2024 | | | |
| 103 | ATAZANAVIR SULPHATE (addition of PSS) → Cap 200 mg – 5% DV Jun-24 to 2025 | 110.00 | 60 | Atazanavir Viatrix |

NERVOUS SYSTEM

| | | | | |
|-----|---|-------|--------|---------------------|
| 122 | MORPHINE SULPHATE (new listing) Oral liq 2 mg per ml | 29.80 | 100 ml | Oramorph CDC S29 |
| 123 | OXYCODONE HYDROCHLORIDE (new listing) Oral liq 1 mg per ml | 37.08 | 250 ml | Oxycodone Lucis S29 |
| 137 | MIDAZOLAM (new listing) Inj 1 mg per ml, 5 ml ampoule | 3.95 | 10 | Midazolam Viatrix |

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

| | | | | |
|-----|---|--------|---|-----------------|
| 147 | CYTARABINE (new listing) Inj 100 mg per ml, 20 ml vial | 48.80 | 1 | Cytarabine DBL |
| 164 | OCTREOTIDE (new listing) → Inj depot 30 mg prefilled syringe | 670.80 | 1 | Sandostatin LAR |
| | Note – Octreotide Depot Teva to be delisted from 1 December 2024 | | | |

VARIOUS

| | | | | |
|-----|--|-------|----|-------------|
| 264 | SODIUM CHLORIDE (↑ price) Irrigation soln 0.9%, 30 ml ampoule | 12.50 | 20 | InterPharma |
|-----|--|-------|----|-------------|

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Index

Pharmaceuticals and brands

| | |
|---|---|
| A | |
| Atazanavir Mylan..... | 6 |
| ATAZANAVIR SULPHATE | 6 |
| Atazanavir Viatrix..... | 6 |
| C | |
| CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE | 5 |
| CIPROFLOXACIN | 5 |
| CYTARABINE | 6 |
| Cytarabine DBL | 6 |
| F | |
| FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE.... | 5 |
| I | |
| Ipca-Ciprofloxacin | 5 |
| L | |
| LEVOSIMENDAN | 5 |
| M | |
| MIDAZOLAM | 6 |
| Midazolam Viatrix..... | 6 |
| MORPHINE SULPHATE | 6 |
| MULTIVITAMINS | 5 |
| N | |
| NADOLOL | 5 |
| Nadolol BNM..... | 5 |
| O | |
| OCTREOTIDE | 6 |
| Oramorph CDC S29 | 6 |
| OXYCODONE HYDROCHLORIDE | 6 |
| Oxycodone Lucis S29 | 6 |
| P | |
| Pabrinex IM..... | 5 |
| Pabrinex IV..... | 5 |
| S | |
| Sandostatin LAR | 6 |
| Simdax | 5 |
| SIMVASTATIN..... | 5 |
| Simvastatin Mylan..... | 5 |
| Simvastatin Viatrix..... | 5 |
| SODIUM CHLORIDE | 6 |
| SULFADIAZINE SODIUM | 5 |
| SULPHADIAZINE | 5 |
| U | |
| Ultraproct..... | 5 |

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

